InvestorsHub Logo
Followers 0
Posts 43
Boards Moderated 0
Alias Born 08/16/2020

Re: None

Friday, 12/03/2021 9:24:12 AM

Friday, December 03, 2021 9:24:12 AM

Post# of 36590
While it appears good that Revive is expanding research to address new variants and add new "markers", it seems that this prolongs the Phase 3 study and we never get to the "finish" line. The study will not benefit anybody if results are never published and an EUA or drug approval keeps being delayed to accommodate additional study criteria. I am interested in hearing other comments regarding this. Y'all have a great day/weekend.